Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Sarcopenia assessments as predictors of overall survival in patients with metastatic renal cell carcinoma.

Kümmerl, L., Kraulich, M., Lesyuk, W., Binninger, A., Goebell, P.J., Kahlmeyer, A., 2023.

Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2023.06.011

Link

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: - / Journal: Urologic Oncology
CARAT
2023
Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.

Kröning H, Göhler T, Decker T, Grundeis M, Kojouharoff G, Lipke J, Semsek D, Moorahrend E, Sauer A, Bruch HR, Liersch R, Nusch A, Vehling-Kaiser U, Welslau M, Grunewald R, Harich HD, Stephany M, Uhlig J, de Buhr R, Frank M, Hogrefe C, Marschner N, Potthoff K, Hartmann F, Reisländer T, Schwaner I.

Int J Cancer. 2023 Sep 15;153(6):1227-1240. doi: 10.1002/ijc.34603. Epub 2023 Jun 1.

Link

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: - / Journal: International Journal of Cancer
TACTIC
2023
Real-world Daten zur Erhaltungstherapie mit Durvalumab nach definitiver Strahlenchemotherapie bei Patienten mit Nicht-Kleinzelligem Lungenkarzinom in lokal fortgeschrittenen Stadien: Daten aus der Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315)

M. Stuschke, F. Griesinger, M. Thomas, A. Gröschel, P. Christopoulos, M. Reck, P. Ludwig, A. Hipper, L. Spring, A. Andres-Pons, M. Jänicke, S. Dörfel, M. Bendel, K. Kokowski, B. Passlick, M. Sebastian, W.E.E. Eberhardt.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: - / Journal: -
CRISP
2023
PCI in der metastasierten Situation beim SCLC in real world: Daten aus der Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315)

T. Gauler, R. Fischer, M. Reck, C. Grah, M. Heilmann, P. Ludwig, A. Hipper, N. Wetzel, T. Medinger, A. Binninger, M. Jänicke, P. Hoffknecht, W. Gleiber, F. Griesinger, M. Thomas, W. E. E. Eberhardt, C. F. Waller, M. Sebastian, 2023.

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DEGRO / Journal: -
CRISP
2023
Outcomes of patients with locally advanced or metastatic pancreatic cancer treated with different sequential treatment strategies –data from the prospective Tumour Registry Pancreatic Cancer.

S Hegewisch-Becker; M Reiser; S Dörfel; C Lerchenmüller; H Linde; T Wolf; A Binninger; N Wetzel; M Jänicke; N Marschner, 2022.

Oncol Res Treat 2022;45(suppl 1):80

Download

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: DKK / Journal:
TPK
2022
Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+ / HR+ early breast cancer (eBC).

D Lüftner; R Bartsch; U Breitenstein; M Balic; C Jackisch; V Müller; G Rinnerthaler; M Schmidt; M Schwitter; K Zaman; D Wrobel; D Guth; J Terhaag; M Zaiss; A Distelrath; A Lorenz; T Schinköthe; N Harbeck, 2022.

Oncol Res Treat 2022;45(suppl 1):19

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
ELEANOR
2022
Sequential treatment patterns over time for advanced renal cell carcinoma: data from the German research platform CARAT.

P J Goebell; C Grüllich; L Müller; M Bögemann; U Martens; E von der Heyde; D Reichert; A Nusch; A Schlenska-Lange; N Wetzel; M Koska; M Jänicke; N Marschner; M Staehler; V Grünwald, 2022.

Oncol Res Treat 2022;45(suppl 1):796

Download

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DKK / Journal: Oncology Research and Treatment
CARAT
2022
First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Final results of the NEPTUN study

Dechow T, Riera-Knorrenschild J, Hackanson B, Janssen J, Schulz H, Oppermann U, Chiabudini M, von Weikersthal LF, Budweiser S, Nacke A, Taeuscher D, Welslau M, Potthoff K. .

Int J Cancer. 2023 Jul 1;153(1):141-152. doi: 10.1002/ijc.34467. Epub 2023 Mar 8.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: / Journal: International Journal of Cancer

NEPTUN
2023
The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice

Martens UM, Schröder J, Bengsch F, Sellmann L, Busies S, Frank-Gleich S, Zaiss M, Decker T, Schneeweiss A, Schuler M, Grebhardt S, Zacharias S, Marschner N, Kasenda B, Potthoff K, Vannier C.

BMC Cancer. 2023 Jun 13;23(1):543. doi: 10.1186/s12885-023-11046-3

Link

Download

Indikation: Präzisionsonkologie, Precision Oncology / Veranstaltung: / Journal: BMC Cancer
INFINITY
2023
Tucatinib in patients with locally advanced or metastatic HER2-positive breast cancer who received at least two prior anti-HER2 treatment regimens: Study design of the non-interventional study TRACE in Germany and Austria

N. Harbeck , R. Bartsch , V. Müller , M. Balic , D. Egle , E. Schumacher-Wulf , M. Angerer , A. Nusch , C. Uleer , M. Welslau , J. Radosa , D. Wrobel , R. de Buhr , M. Glasstetter , J. Hanselmann , C. Hogrefe , N. Marschner ,K. Gratzke , A. Welt

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: Senologie Kongress / Journal:
TRACE
2023